|
WO2021052349A1
|
|
Gipr antibody and fusion protein between same and glp-1, and pharmaceutical composition and application thereof
|
|
WO2020248967A1
|
|
Fusion protein of eta antibody and bnp, and pharmaceutical composition and application of fusion protein
|
|
CN112239507A
|
|
Fusion protein of ETA antibody and TGF-beta Trap, and pharmaceutical composition and application thereof
|
|
CA3103585A1
|
|
Apj antibody and its fusion protein with elabela, and pharmaceutical composition and application thereof
|
|
WO2018188612A1
|
|
Bispecific antibody capable of being combined with human cd19 or cd20 and human cd3, and applications thereof
|
|
CN110357959A
|
|
GCGR antibody and its with the fused protein of GLP-1 and its pharmaceutical composition and application
|
|
CN110305211A
|
|
GIPR antibody and its with the fused protein of GLP-1 and its pharmaceutical composition and application
|
|
EP3476864A1
|
|
Etar antibody, pharmaceutical composition and use thereof
|
|
CN107987162A
|
|
ETAR antibody, its pharmaceutical composition and its application
|
|
EP3257524A1
|
|
Stabilized solution preparation of pharmaceutical glp-1r antibody fusion protein
|
|
CN111018987A
|
|
Antibody capable of being specifically bound with human endothelin receptor and application thereof
|
|
KR20160055789A
|
|
Antibody specifically binding to glp-1r and fusion protein thereof with glp-1
|
